Google
BBLGW — BONE BIOLOGICS CORP WARRANTS
BBLGW FAQ
What is BBLGW's ROE?
BONE BIOLOGICS CORP WARRANTS reports a Return on Equity (ROE) of -61.20%.
What is BBLGW's dividend yield?
BONE BIOLOGICS CORP WARRANTS offers a dividend yield of 0.00%.
What is BBLGW's Deepscope Quality Score?
Deepscope rates BBLGW's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BBLGW?
Deepscope's AI Timing Score for BBLGW is 2 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
|
USD 15.34
Price
1.34
(9.57%)
Day Change
|
|
|---|
BBLGW, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 15.34 |
| PBV / Sector |
N/A / N/A
|
| Earning Per Share | N/A |
| PE / Sector |
N/A / N/A
|
| PEG or PE/Growth / Sector |
N/A / N/A
|
| Average 1M Daily Value |
0.01 M
GREAT
|
| Average 1W Daily Value |
0.02 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2 Burlington Woods Drive, Burlington, MA, United States, 01803
Phone: 781 552 4452
Website: https://www.bonebiologics.com
Sector: -
Description: Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
ME vs SECTOR
Click a bubble to view stock details · Bubble size represents market capitalization share
